NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic
NeoGenomics announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca's recently approved targeted the